Home  /  Resource Library  /  Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma

Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma

ASH 2020: Results of a study examining Ixazomib maintenance following autologous stem cell transplant for treatment of MCL.